A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

NCT01245166 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg
Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
Subjects With Type 2 Diabetes Mellitus.

Interventions

DRUG: Acarbose
DRUG: Metformin/Acarbose

Sponsor

Lotus Pharmaceutical